Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial

Abstract Introduction Evolocumab, a fully human proprotein convertase/subtilisin kexin type 9 inhibitor antibody, significantly lowers low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes mellitus and hyperlipidemia and mixed dyslipidemia. This 12-week study evaluated the eff...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hong Tan, Weimin Li, Zhouqing Huang, Yajun Han, Xuecheng Huang, Dongye Li, Xiaochun Xing, Maria Laura Monsalvo, You Wu, Jackie Mao, Lily Xin, Jiyan Chen, HUA TUO study investigators
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2023-02-01
Colecção:	Cardiology and Therapy
Assuntos:	Evolocumab Hypercholesterolemia Mixed dyslipidemia LDL cholesterol PCSK9 Hyperlipidemia
Acesso em linha:	https://doi.org/10.1007/s40119-023-00304-x
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!